None listed
Conditions
Interventions
Tobramycin Remimazolam Group (Experimental Group):Induction dose 12mg/kg/h
Maintenance method Continuous intravenous infusion (0.6-1.0mg/kg/h)
Propofol group (control group):Induction dose TCI 4 ug/ml
Maintenance mode Target concentration 2.5-4.0 µg/ml
Sponsors
The First Affiliated Hospital of Harbin Medical University
Eligibility
Sex/Gender
All
Age
65 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Age 65–80 years (inclusive of 65 years), undergoing elective surgery under general anesthesia, excluding cardiac and neurosurgical procedures. 2. American Society hesiologists (ASA) physical status classification II–III. 3. Anticipated anesthesia duration of not less than 60 minutes and not exceeding 120minutes. 4. Body Mass Index (BMI) of 18.5–28 kg/m^². 5. Full understanding of this trial and provision of written infor
Exclusion criteria
Exclusion criteria: 1. Allergy to anesthetic drugs specified in the protocol. 2. Preoperative cognitive impairment, or the presence of hearing, language communication, motor intellectual disabilities. 3. Severe hepatic or renal insufficiency, combined with severe cardiovascular or pulmonary disease. 4. Long-term use of analgesic drpsychotropic medications. 5. History of psychiatric or neurological disorders, such as depression, epilepsy, or cerebral infarction. 6. History of craniocerebrargery or delirium. 7. Alcohol abuse within the past 3 months (defined as an average daily alcohol intake >2 units, where 1 unit =360 mL beer, 45 mL of 40% alcohol liquor, or 150 mL wine). 8. Undergone other surgeries under general anesthesia within the pst 3 months. 9. Poor adhesion or failure of disposable electroencephalogram (EEG) sensors, severely compromising EEG monitoring quality. 10. Other conditions dinvestigator as unsuitable for continuing participation in this trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| SSD incidence rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| BSR;SEF95;Alpha/Beta power ratio;Incidence of intraoperative hypotension/bradycardia;PONV;injection pain;LOC duration;QoR-15 recovery quality score on postoperative day 1;Duration of Stay in the Post-Anesthesia Care Unit;Postoperative Visual Analogue Scale Score;Intraoperative awareness;RASS score after extubation;duration of extubation;recovery time; | — |
Countries
China
Contacts
Public ContactKun Wang
The First Affiliated Hospital of Harbin Medical University
Outcome results
None listed